



NEW YORK CITY DEPARTMENT OF
HEALTH AND MENTAL HYGIENE
Dave A. Chokshi, MD MSc
Commissioner

December 21, 2021

Dear Colleagues,

The New York City Department of Health and Mental Hygiene is writing to provide an update on monoclonal antibody (mAb) treatment recommendations. According to the most recent [CDC projections](#), Omicron is estimated to account for 92% of new COVID-19 cases in the region (which includes New York, New Jersey, Puerto Rico, and US Virgin Islands). [Studies conducted by the FDA and others](#) have demonstrated that bamlanivimab with etesevimab and Regen-Cov **do not** retain activity against the Omicron variant. [Sotrovimab is expected to retain full potency](#) against Omicron.

Current New York State allocations and national supplies of Sotrovimab are extremely limited so we ask you to please adhere to New York State Department of Health (NYSDOH) [guidance on prioritization of mAbs during periods of resource shortages](#). Providers should focus on use of mAbs as treatment for COVID-19 over post-exposure prophylaxis (PEP) and prioritize patients ages 65 and older and people with moderate to severe immunocompromise, regardless of vaccination status.

For information on ordering mAbs and allocation, please refer to NYSDOH's [COVID-19 Monoclonal Antibody \(mAb\) Therapeutics Information for Providers](#) or email COVID19therapeutics@health.ny.gov. For details on authorized products and the updates on COVID-19 therapeutics, visit the NYC Department of Health and Mental Hygiene's [COVID-19 Outpatient Therapeutics webpage](#) and the US Department of Health and Human Service's [COVID-19 Monoclonal Antibody Therapeutics webpage](#).

Regards,

A handwritten signature in black ink, appearing to be "C Quinn", with a long horizontal flourish extending to the right.

Celia Quinn, MD, MPH